web sites all sites choose country argentinaaustraliaaustriabelgium luxembourgbrazilcanadachinaczech republicdenmarkfrancegermanyitalyjapanmexiconetherlandsnordicspainswitzerlandukusacsl plasma uscsl plasma germany home about csl behring products patient commitment health safety & environment quality & safety csl research & development clinical trials other areas of business news room careers contact us home home product overview csl behring develops manufactures and markets protein based therapies including bleeding disorders therapies fluid replacement therapies hereditary angioedema hae therapies immunoglobulin therapies pulmonary therapies wound healing therapies global product portfolio featurespaul perreault talks about innovationpaul perreault on bloomberg news if you re not innovating in this rare disease space you re planning your exit . personal storiestim s story outdoor adventurer remains active despite hemophilia interview with csl ceo paul perreault on fox business newspaul perreault talks about csl s r & d spend the hemophilia space and csl s strategies for growth . news07 october 2016plasma donors recognized for their contributions 03 october 2016idelvion approved in australia 29 september 2016idelvion approved in japan 21 september 2016csl behring is proud sponsor of the 17th biennial esid ... 16 september 2016greg boss receives distinguished general counsel award 06 september 2016csl behring hosts forum on modifying alpha1 related ... view all news share more options contact us report undesirable effect enews signup site map global privacy policy terms of use 2016 csl behring